

# Polygenic Score Workshop

Part 2: Evaluating Polygenic Scores

#### **Jodi Thomas**

24<sup>th</sup> July 2025

Adelaide Medical School




### Using Statistics to Evaluate PGS


- Data
- Statistics to evaluate PGS
  - Regression
  - $\bullet$  R<sup>2</sup>
  - Nagelkerke's R<sup>2</sup>
  - R<sup>2</sup> on the liability scale
  - Odds Ratio by decile of PGS
  - AUC

- Applications
- Limitations
- Example





















FID	IID	PGS	Sex	PC1	PC2	PC3	PC4	PC5	PC6	Epilepsy
HG00096	HG00096	-0.03122	1	0.000643	0.066432	-1.47E-02	-0.036	-0.01636	-0.02094	0
HG00097	HG00097	0.007768	2	0.001414	0.073602	8.82E-03	-0.02058	-0.01168	0.022409	0
HG00099	HG00099	-0.04946	2	0.002647	0.07177	-2.10E-02	-0.00609	-0.01414	-0.00713	0
HG00101	HG00101	-0.01496	1	0.001698	0.085445	-1.57E-02	-0.00289	-0.03352	-0.01412	1
HG00102	HG00102	-0.04752	2	0.004411	0.069636	1.76E-06	-0.02643	-0.04776	-0.03145	0
HG00103	HG00103	-0.02364	1	-0.00431	0.057179	-8.19E-03	-0.01349	0.015997	-0.01207	0





#### **Binary Traits**

## **Continuous Traits**

### Regression

- Regression model: Trait ~ PGS + covariates
- Linear regression for continuous trait (e.g. height)
- Logistic regression for binary trait (e.g. case/control)



Continuous Traits

### Regression

- Regression model: Trait ~ PGS + covariates
- Linear regression for continuous trait (e.g. height)
- Logistic regression for binary trait (e.g. case/control)
- Is there a significant association between trait and PGS?
- Is the association in the expected direction?



## R<sup>2</sup> (Variance Explained)

• From the **linear regression**, estimate the R<sup>2</sup> that is attributable to the PGS

- $R^2$ (full model)  $R^2$ (covariates only model)
- Proportion of variance in the outcome variable explained by the PGS



## R<sup>2</sup> (Variance Explained)

- Advantage
  - Comparable to SNP-based heritability  $(h^2)$

- <u>Limitation</u>
  - R<sup>2</sup> can't be compared across outcome traits on different scales (make sure to standardise outcome traits to allow comparison)



## Nagelkerke's R<sup>2</sup>

• From the **logistic regression**, estimate Nagelkerke's R<sup>2</sup> that is attributable to the PGS

- Nagelkerke's R<sup>2</sup>(full model) Nagelkerke's R<sup>2</sup>(covariates only model)
- A pseudo-R<sup>2</sup> value from 0 1
- A relative measure of model fit representing an approximation of explained variance



## Nagelkerke's R<sup>2</sup>

- Advantage
  - A familiar metric that is easy to compute
- <u>Limitations</u>
  - A relative measure of fit and can't be interpreted as 'proportion of variance explained' like linear R<sup>2</sup>
  - On the binary observed scale
    - This depends on the case/control ratio in your sample
    - Can't be compared across studies with different case/control ascertainment
  - Is not comparable to SNP-based heritability (h²)



## Liability R<sup>2</sup>

- Steps
  - Run linear regression (even though outcome is binary)
  - Adjust R<sup>2</sup> to the liability scale
  - R<sup>2</sup> liability (full model) R<sup>2</sup> liability (covariates only model)

 Proportion of variance in the unobserved liability (risk) for a binary trait that is explained by the PGS



### Observed R<sup>2</sup>

- Explains variation in case/control status
- Depends on case/control ratio in sample


Controls

Cases






## Liability R<sup>2</sup>





## Liability R<sup>2</sup>

- Assumes there's an underlying continuous risk for disease
- Adjusts for both population disease prevalence and sample ascertainment
- Proportion of variance in the underlying continuous, unobserved liability (or risk) that is explained by the PGS



Lee SH, et al., A Better Coefficient of Determination for Genetic Profile Analysis. Genetic Epidemiology, 2012. 36(3):214-224.

Observed R<sup>2</sup> from linear regression

#### **Calculate constants:**

- K = population prevalence
- P = sample prevalence
- t = the threshold on the normal distribution which truncates the proportion of disease prevalence
- z = density at t
- m = mean liability = z/K

### Compute C and θ using formulas:

• 
$$C = \frac{K(1-K)}{z^2} \frac{K(1-K)}{P(1-P)}$$

$$\bullet \quad \theta = m \, \frac{P - K}{1 - K} \left( m \frac{P - K}{1 - K} - t \right)$$

#### Calculate liability R<sup>2</sup>:

$$R^2_{liability} = \frac{R^2_{observed}C}{1 + R^2_{observed}\theta C}$$



## Liability R<sup>2</sup>

- Advantages
  - Can compare across studies
  - Comparable to SNP-based heritability (h²)

- <u>Limitations</u>
  - Requires the population prevalence of the trait
  - Assumes an underlying liability threshold model




### Odds Ratio by Decile of PGS

- Cut PGS distribution into deciles
- Run logistic regression: Trait(case/control) ~ PGS(deciles) + covariates
- Odds ratio of each PGS decile compared to the:
  - First (lowest) PGS decile
  - Middle PGS decile (more recently)


### 8 Group Females (N = 15,588) Males (N = 9,141)6-Depression Odds Ratio 95% CI 2 3 5 6 8 MDD PGS Decile

Mitchell BL, et al., The Australian Genetics of Depression Study: New risk loci and dissecting heterogeneity between subtypes. Biol Psychiatry, 2022. 92(3):227-235.

#### **Binary Traits**




#### **Binary Traits**



Mitchell BL, et al., The Australian Genetics of Depression Study: New risk loci and dissecting heterogeneity between subtypes. Biol Psychiatry, 2022. 92(3):227-235.

Adams MJ, et al., Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies. Cell, 2025. 188:1-13.





### Odds Ratio by Decile of PGS

- Advantage
  - Practical and interpretable way to visualise risk stratification

#### <u>Limitations</u>


- Doesn't take into account proportion of cases and controls in your data
  - Will look much more impressive if you have a data set with 50% cases and 50% controls, compared to a population sample.
- Categorising PGS into deciles loses information



#### **AUC**

- Area Under the Receiver Operating Characteristic Curve
- Probability that a randomly selected case has a higher PGS than a randomly selected control
  - 0.5 = no discrimination of cases and controls
  - 1 = perfect discrimination

#### **Binary Traits**



Mitchell BL, et al., Genome-wide association meta-analysis identifies 29 new acne susceptibility loci. Nat Commun, 2022. 13(1):702.



### **AUC**

- Advantages
  - Well established measure
  - Independent to proportion of cases and controls in sample

#### <u>Limitations</u>

- Problem with genetic interpretation
  - PGS is a proxy (AUC is limited by how well the PGS captures genotype—phenotype associations)
  - The maximum AUC achievable depends on the heritability of the disease
  - A low AUC doesn't necessarily mean genetics don't matter



### Best to report multiple measures

# Make your results accessible to both geneticists and clinicians



## Applications Applications

<b>Discovery Sample</b>	Target Sample	Application	Biological Insight
Disorder A	Disorder A	Show polygenicity	PGS can predict outcomes even without genome-wide hits
Disorder A	Disorder B	Test pleiotropy	Reveals shared genetic architecture between conditions
Disorder A	Subtypes of Disorder A	Investigate heterogeneity	Subtypes may have distinct genetic contributions
Disorder A	Disorder A + environment data	Explore GxE	Genes may act differently depending on environmental context
Disorder A	Environmental exposure or presence of a trait	Explore gene-environment/trait correlations	Certain exposures/traits may be genetically linked
Disorder A	General population / clinical cohorts	Identify at-risk individuals	Risk stratification to identify individuals at high genetic risk



### Limitations

- Individual-level prediction is not accurate enough for most phenotypes
  - Not reliable for individual diagnosis or decision-making
- Difficult to interpret what the PGS is truly capturing
  - Includes many variants with unknown function
  - Predictive power may reflect not only the causal effect of genetic variants but also gene-environment correlations, population stratification, indirect genetic effects, assortative mating
- Poor transferability across ancestries
  - PGS mainly developed in European populations and underperform when used in other ancestries



### Example



Do polygenic scores (PGS) for Cerebral Palsy and comorbid traits associate with Cerebral Palsy?

These slides from the workshop have been removed due to being unpublished results





#### Dr. Jodi Thomas Research Officer



jodi.thomas@qimrb.edu.au

Github Repository
Polygenic Score Workshop

https://github.com/jodithea/ Polygenic\_score\_workshop

